John Liles

Company: Gilead Sciences

Job title: Director, Biology

Seminars:

Panel Discussion: Identifying & Validating a Novel Therapy to Complement SGLT2 Inhibitors 9:30 am

Defining the next wave of therapeutics discovery after SGLT2i to improve clinical outcomes Measuring incremental benefit of novel therapeutics in addition to SGLT2 inhibitors Optimizing a smart preclinical screening platform to monitor efficacy in addition to standard of care Considering innovative trial design and untraditional endpoints to demonstrate efficacy and meet regulatory requirementsRead more

day: Day Two